ImmunoGen, Inc. ' Product Pipeline Review ' 2012

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

ImmunoGen, Inc. ' Product Pipeline Review ' 2012
Published on August 2012

Report Summary


Summary

Global Markets Direct's pharmaceuticals report, 'ImmunoGen, Inc. - Product Pipeline Review - 2012' provides data on the
ImmunoGen, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete
with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, ImmunoGen, Inc.'s
corporate website, SEC filings, investor presentations and featured press releases, both from ImmunoGen, Inc. and industry-specific
third party sources, put together by Global Markets Direct's team.

Scope

- ImmunoGen, Inc. - Brief ImmunoGen, Inc. overview including business description, key information and facts, and its locations and
subsidiaries.
- Review of current pipeline of ImmunoGen, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities,
across the globe.
- Product profiles for late stage and clinical stage products of ImmunoGen, Inc. with complete description of the product's
developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the ImmunoGen, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate ImmunoGen, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of ImmunoGen, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the ImmunoGen, Inc.'s R&D portfolio and develop key strategic initiatives to
reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with ImmunoGen, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ImmunoGen, Inc. and identify potential opportunities in those areas.

ImmunoGen, Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 1/7


Table of Content

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
ImmunoGen, Inc. Snapshot 7
ImmunoGen, Inc. Overview 7
Key Information 7
Key Facts 7
ImmunoGen, Inc. ' Research and Development Overview 8
Key Therapeutic Areas 8
ImmunoGen, Inc. ' Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products ' Monotherapy 12
Pipeline Products ' Combination Treatment Modalities 13
ImmunoGen, Inc. ' Pipeline Products Glance 14
ImmunoGen, Inc. Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
ImmunoGen, Inc. ' Early Stage Pipeline Products 16
Pre-Clinical Products/Combination Treatment Modalities 16
ImmunoGen, Inc. ' Drug Profiles 17
Cancer Program 1 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Cancer Program 2 18
R&D Progress 18
Cancer Program 3 19
R&D Progress 19
huHER3-8 20
R&D Progress 20
IMGN529 21
R&D Progress 21
IMGN853 22



R&D Progress 22
IMGN901 23
R&D Progress 23
IMGN901 + Carboplatin + Etoposide 25
R&D Progress 25
IMGN901 + Revlimid + Dexamethasone 26
R&D Progress 26
SAR 566658 28
R&D Progress 28
ImmunoGen, Inc. ' Pipeline Analysis 30
ImmunoGen, Inc. ' Pipeline Products by Therapeutic Class 30
ImmunoGen, Inc. ' Pipeline Products by Route of Administration 31
ImmunoGen, Inc. ' Pipeline Products By Mechanism of Action 32
ImmunoGen, Inc. ' Recent Pipeline Updates 33
ImmunoGen, Inc. - Dormant Projects 37
ImmunoGen, Inc. - Discontinued Pipeline Products 38
Discontinued Pipeline Product Profiles 38
AVE1642 38
AVE1642 + Erlotinib 38
AVE1642 + Faslodex 38
AVE1642 + Sorafenib 39
AVE1642 + Velcade 39
AVE9633 39
IMGN242 39
IMGN388 40
ImmunoGen, Inc. ' Company Statement 41
ImmunoGen, Inc. ' Locations And Subsidiaries 44
Head Office 44
ImmunoGen, Inc. - Key Manufacturing Facilities 45
ImmunoGen, Inc., Recent Developments 46
ImmunoGen, Inc.- Press Release 46
Jul 11, 2012: ImmunoGen Initiates Phase I Trial Of IMGN853 In Ovarian Cancer And Other Solid Tumors Over-Expressing Folate
Receptor Target 46
Apr 17, 2012: ImmunoGen Announces IND Application Now Active For IMGN853 46
Apr 17, 2012: ImmunoGen Initiates Phase I Trial Of IMGN529 In Non-Hodgkin's Lymphoma 47
Mar 30, 2012: ImmunoGen Initiates Phase II Evaluation Of IMGN901 In Small Cell Lung Cancer 48
Dec 06, 2009: ImmunoGen, Inc. Announces Encouraging Clinical Data With Its IMGN901 Compound In The Treatment Of Multiple
Myeloma 49
Nov 17, 2009: ImmunoGen, Inc. Announces Encouraging Clinical Data With Its IMGN901 Compound In The Treatment Of Merkel Cell
Carcinoma 50



Jul 31, 2009: ImmunoGen Announces Encouraging New Clinical Data With IMGN901 Compound In The Treatment Of Small-Cell
Lung Cancer 51
Jun 11, 2009: ImmunoGen, Inc. Announces The Discontinuation Of Further Internal Development Of Its IMGN242 Compound 52
Jun 01, 2009: Sanofi-Aventis Terminates Licensing With Immunogen For AVE 1642 52
Financial Deals Landscape 53
ImmunoGen, Inc., Deals Summary 53
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Deal Details 54
Partnerships 54
ImmunoGen Enters Into Partnership With Novartis 54
Sanofi-Aventis Extends Research Collaboration With ImmunoGen 56
Licensing Agreements 58
ImmunoGen Extends Its License Agreement With Sanofi-Aventis 58
ImmunoGen Enters Into Licensing Agreement With Eli Lilly 59
ImmunoGen Enters Into Second Licensing Agreement With Amgen 61
ImmunoGen Enters Into Licensing Agreement With Amgen 62
ImmunoGen Enters Into Licensing Agreement With Genentech For Cancer Technology 63
ImmunoGen Enters Into Licensing Agreement With Bayer HealthCare 64
ImmunoGen Enters Into Licensing Agreement With Centocor Ortho Biotech 65
ImmunoGen Enters Into Licensing Agreement With Sanofi-Aventis 67
ImmunoGen Enters Into Licensing Agreement With Biotest 68
ImmunoGen Extends Its Agreement With Millennium Pharma 69
Equity Offering 70
ImmunoGen Prices Public Offering Of Common Stock For $100 Million 70
ImmunoGen Completes An Underwritten Public Offering Of $84 Million 72
ImmunoGen Completes Public Offering Of $83 Million 74
ImmunoGen Completes Private Placement Of $25 Million 78
Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 81
Disclaimer 81

List of Tables

ImmunoGen, Inc., Key Information 7
ImmunoGen, Inc., Key Facts 7
ImmunoGen, Inc. ' Pipeline by Indication, 2012 10
ImmunoGen, Inc. ' Pipeline by Stage of Development, 2012 11
ImmunoGen, Inc. ' Monotherapy Products in Pipeline, 2012 12
ImmunoGen, Inc. ' Combination Treatment Modalities in Pipeline, 2012 13
ImmunoGen, Inc. ' Phase II, 2012 14
ImmunoGen, Inc. ' Phase I, 2012 15
ImmunoGen, Inc. ' Pre-Clinical, 2012 16
ImmunoGen, Inc. ' Pipeline By Therapeutic Class, 2012 30



ImmunoGen, Inc. ' Pipeline By Route of Administration, 2012 31
ImmunoGen, Inc. ' Pipeline Products By Mechanism of Action, 2012 32
ImmunoGen, Inc. ' Recent Pipeline Updates, 2012 33
ImmunoGen, Inc. - Dormant Developmental Projects,2012 37
ImmunoGen, Inc. - Discontinued Pipeline Products, 2012 38
ImmunoGen, Inc., Key Manufacturing Facilities 45
ImmunoGen, Inc., Deals Summary 53
ImmunoGen Enters Into Partnership With Novartis 54
Sanofi-Aventis Extends Research Collaboration With ImmunoGen 56
ImmunoGen Extends Its License Agreement With Sanofi-Aventis 58
ImmunoGen Enters Into Licensing Agreement With Eli Lilly 59
ImmunoGen Enters Into Second Licensing Agreement With Amgen 61
ImmunoGen Enters Into Licensing Agreement With Amgen 62
ImmunoGen Enters Into Licensing Agreement With Genentech For Cancer Technology 63
ImmunoGen Enters Into Licensing Agreement With Bayer HealthCare 64
ImmunoGen Enters Into Licensing Agreement With Centocor Ortho Biotech 65
ImmunoGen Enters Into Licensing Agreement With Sanofi-Aventis 67
ImmunoGen Enters Into Licensing Agreement With Biotest 68
ImmunoGen Extends Its Agreement With Millennium Pharma 69
ImmunoGen Prices Public Offering Of Common Stock For $100 Million 70
ImmunoGen Completes An Underwritten Public Offering Of $84 Million 72
ImmunoGen Completes Private Placement Of $25 Million 78

List of Figures

ImmunoGen, Inc. ' Pipeline by Indication, 2012 9
ImmunoGen, Inc. ' Pipeline by Stage of Development, 2012 11
ImmunoGen, Inc. ' Monotherapy Products in Pipeline, 2012 12
ImmunoGen, Inc. ' Combination Treatment Modalities in Pipeline, 2012 13
ImmunoGen, Inc. ' Pipeline By Route of Administration, 2012 31
ImmunoGen, Inc. - Pipeline Products By Mechanism of Action, 2012 32


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 1 500.00 Quantity: _____

Site License--USD 3 000.00 Quantity: _____

Corporate License--USD 4 500.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


ImmunoGen, Inc. ' Product Pipeline Review ' 2012

Recomendados

Recomendados

Más contenido relacionado

Más de ReportLinker.com

Más de ReportLinker.com (20)

ImmunoGen, Inc. ' Product Pipeline Review ' 2012